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Purpose. The peptide transporter PEPT2 was recently shown to be
functionally active in rat choroid plexus, suggesting that it may play a
role in neuropeptide homeostasis in the cerebrospinal fluid. This
study, therefore, examined the role of PEPT2 in mediating neuro-
peptide uptake into choroid plexus.
Methods. Whole-tissue rat choroid plexus uptake studies were per-
formed on GlySar in the absence and presence of neuropeptides and
on carnosine.
Results. The neuropeptides NAAG, CysGly, GlyGln, kyotorphin,
and carnosine inhibited the uptake of radiolabeled GlySar at 1.0 mM
concentrations. In contrast, TRH, [D-Arg2]-kyotorphin, glutathione,
and homocarnosine did not inhibit GlySar uptake. Kyotorphin, an
analgesic, was a competitive inhibitor of GlySar with a Ki of 8.0 mM.
The direct uptake of carnosine was also shown to be mediated by
PEPT2 in isolated choroid plexus (Km 4 39.3 mM; Vmax 4 73.9
pmol/mg/min). Radiolabeled carnosine uptake was inhibited by 1.0
mM concentrations of GlySar or carnosine but not homocarnosine,
L-histidine, or b-alanine.
Conclusions. These findings indicate that PEPT2 mediates the up-
take of a diverse group of neuropeptides in choroid plexus, and sug-
gests a role for PEPT2 in the regulation of neuropeptides, peptide
fragments, and peptidomimetics in cerebrospinal fluid.
KEY WORDS: PEPT2; GlySar; carnosine; neuropeptides; choroid
plexus.
INTRODUCTION
PEPT2, a member of the proton-oligopeptide trans-
porter family, is a Na+-independent symporter that moves
peptides and protons across biological membranes. It is con-
sidered to be of high affinity and low capacity with a Km in
the micromolar region, and is primarily located in the kidney,
lung, and brain (1–3). Recently, PEPT2 has been localized in
choroid plexus by mRNA analysis (4) and immunoblotting
(5). The peptide-histidine transporter PHT1, which transports
histidine and small peptides with high affinity and in a proton
gradient-dependent manner, has also been localized in cho-
roid plexus (6). These two transporters show little homology
(< 20% amino acid identity), but seem to have overlapping
substrate specificity. Despite the similarities in substrate
specificity, PEPT2, but not PHT1, is involved in the uptake of
glycylsarcosine (GlySar), a hydrolysis and peptidase resistant
dipeptide in choroid plexus (7).
The choroid plexus is known to control the contents of
the cerebrospinal fluid (CSF) via multiple transport systems
(8). This homeostatic control ensures that the CSF maintains
appropriate ionic composition, nutrient content, and pH (8,9).
Our laboratory recently demonstrated that the high-affinity
peptide transporter, PEPT2, is expressed and functionally ac-
tive in rat choroid plexus tissue, while PEPT1 is absent (5,7).
The presence of this peptide transporter in choroid plexus
raises questions as to its physiologic purpose at the blood-CSF
barrier. Peptide transporters are known to serve as a nutritive
transporter in the intestine and as a mechanism of peptide
conservation in the kidney (2,10). Thus, PEPT2 in choroid
plexus may serve a nutritive role by supplying peptides from
the blood circulation to the choroid plexus and CSF. Alter-
natively, it may serve as a clearance mechanism to clear pep-
tide fragments, neuropeptides, and peptidomimetics from the
CSF.
Neuropeptides function as neurotransmitters, neuro-
modulators, and hormones in the central nervous system. We
hypothesize that PEPT2 is involved in the homeostatic con-
trol of these peptides at the blood-CSF barrier located at the
choroid plexus. As a first step to test this hypothesis, several
neuropeptides (Fig. 1) were evaluated as potential inhibitors
of GlySar uptake in isolated rat choroid plexus or as sub-
strates for PEPT2 in this tissue. They include carnosine, cy-
stylglycine (CysGly), glutathione (GSH), gylcylglutamine
(GlyGln), homocarnosine, N-acetylaspartylglutamate
(NAAG), thyrotropin releasing hormone (TRH), kyotorphin
(KTP), and one structural analog, [D-Arg2]-kyotorphin
(DKTP). These compounds were selected because they are
all di- or tripeptides, and they have physiological and phar-
macological relevance in the brain. Understanding the ho-
meostasis of these peptides and mimetics could have impor-
tant implications for the treatment of CNS disorders and for
providing new strategies in drug design, delivery, and target-
ing to the brain.
With this in mind, the objective of this study is to deter-
mine the relative affinity of a diverse group of neuropeptides
for PEPT2 using the in vitro method of isolated rat choroid
plexus uptake. This study also evaluates the inhibitory mecha-
nism of KTP and the direct transport of a neuropeptide, car-
nosine, by PEPT2 in whole tissue choroid plexus.
MATERIALS AND METHODS
Materials
[14C]GlySar (119 mCi/mmol) was purchased from Am-
ersham (Chicago, IL) and [3H]mannitol (19.9 Ci/mmol) from
New England Nuclear Life Science Products (Boston, MA).
[3H]Carnosine (9 Ci/mmol) was purchased from Moravek
Biochemicals (Brea, CA) and [14C]mannitol (53 mCi/mmol)
was purchased from American Radiolabeled Chemicals (St.
Louis, MO). Amino acids (b-alanine and L-histidine),
NAAG, TRH, CysGly, GlyGln, KTP, DKTP, GSH, L-
carnosine, and L-homocarnosine were purchased from Sigma
(St. Louis, MO). Nitex nylon monofilament screening fabric
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(118 micron mesh opening) was purchased from Sefar
America Inc. (Kansas City, MO). Other chemicals were ob-
tained from standard sources and were of the highest quality
available.
Buffers
Bicarbonate artificial cerebrospinal fluid (aCSF) and
Tris-MES buffers were used in the tissue preparation and
uptake experiments. The bicarbonate aCSF buffer (≈305
mOsm/kg) was continuously bubbled with 5% CO2, 95% O2,
and contained 127 mM NaCl, 20 mM NaHCO3, 2.4 mM KCl,
0.5 mM KH2PO4, 1.1 mM CaCl2, 0.85 mM MgCl2, 0.5 mM
Na2SO4, and 5.0 mM glucose (pH 7.3). In experiments where
a low sodium buffer was used, NaCl and NaHCO3 were re-
placed by choline chloride and choline bicarbonate, respec-
tively, producing a 1.0 mM sodium solution due to the pres-
ence of Na2SO4. The low sodium (1.0 mM) Tris-MES buffer
(≈315 mOsm/kg) was continuously bubbled with 100% O2
and contained 147mM choline chloride, 2.4 mM KCl, 0.5 mM
KH2PO4, 1.1 mM CaCl2, 0.85 mM MgCl2, 0.5 mM Na2SO4,
5.0 mM glucose, and 10 mM Tris and/or MES. The pH of the
Tris-MES buffer was adjusted to 6.5 using a combination of
Tris and MES, while holding the osmolarity constant. A pH of
6.5 was previously determined to be the optimum value for
PEPT2-mediated uptake in isolated choroid plexus tissue (7).
GlySar and Carnosine Uptake
Lateral ventricle choroid plexuses were isolated from
anesthetized (pentobarbital, 65 mg/kg i.p.) male Sprague-
Dawley rats aged 30–50 days, as described previously (5,7).
The lateral ventricle plexuses were weighed and transferred
to aCSF buffer at 37°C. There was a 5 min recovery period
prior to the beginning of any experiment. After the recovery
period, the plexuses were transferred to 0.95 ml of uptake
buffer with or without drug for 0.5 min. Uptake was initiated
by the addition of 0.05 ml of the uptake buffer with approxi-
mately 0.1 mCi of [14C]GlySar and 0.2 mCi of [3H]mannitol
(an extracellular marker) or 0.1 mCi of [14C]mannitol and 0.2
mCi of [3H]carnosine. Unless otherwise stated, GlySar uptake
was terminated after 3 min and carnosine uptake was termi-
nated after 1 min by transferring the plexus to ice-cold aCSF
buffer and filtering under reduced pressure. The filters (118
mm mesh) were washed three times with the same buffer. The
filters and choroid plexuses were then soaked in 0.33 ml of 1
M hyamine hydroxide (a tissue solubilizer) for 30 min prior to
the addition of scintillation cocktail (Cytoscint) and counting
with a dual channel liquid scintillation counter (Beckman LS
6000SC; Fullerton, CA). All animal procedures and study
protocols adhered to the “Principles of Laboratory Animal
Care” (NIH publication #85-23, revised 1985).
The uptake of radiolabeled substrate (GlySar or carno-
sine) into choroid plexus, in ml/mg of wet tissue weight, was
calculated according to the following (7)
Substrate Uptake =
St − Sf − @~Mt–Mf!# ? ratio
Smedia
(1)
where St is the total substrate (GlySar or carnosine) concen-
tration in the plexus plus filter, Sf is the filter binding of
substrate, and Smedia is the concentration of substrate in the
external media. The term (Mt–Mf) ? ratio is a correction for
extracellular space where Mt is the total mannitol concentra-
tion in the plexus plus filter, and Mf is the filter binding of
mannitol. Multiplying the difference between these two pa-
rameters by the ratio of [14C]GlySar to [3H]mannitol or
[3H]carnosine to [14C]mannitol in the external medium pro-
vides an estimate of the extracellular content of GlySar or
carnosine, respectively. The unidirectional influx rate (V) can
then be calculated by multiplying Substrate Uptake by Sme-
dia and dividing by duration of the experiment. Filter binding
was <1% of the total uptake, and the extracellular space cor-
rection was 3–5%. Choroid plexuses were not perfused with
saline prior to use and, therefore, some red blood cells are
present in our tissue preparation. However, red blood cells do
not significantly affect substrate uptake, as demonstrated pre-
viously (7).
Data Analysis
For the dose-response studies in which GlySar uptake
can be completely abolished, the inhibitory effect is described
by the model:
Fig. 1. Structures of neuropeptides evaluated in this study. Abbre-
viations defined in text.
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E = Eo ? S IC50n
IC50n + InD (2)
where E is the observed uptake, Eo is the uptake in the
absence of inhibitor, I is the inhibitor concentration, IC50 is
the inhibitor concentration that causes 50% inhibition of
maximal drug effect, and n is the slope factor. The param-
eters, IC50 and n, were estimated for each inhibitory neuro-
peptide by fitting the data to Eq. 2 using nonlinear regression.
KTP inhibited the uptake of GlySar (V) in a competitive




Km ? S1 + IKiD + C
(3)
where Vmax is the maximal rate of GlySar uptake, Km is the
Michaelis constant, Ki is the inhibition constant, and C is the










? S1 + KmC D (4)
By plotting 1/V vs. inhibitor concentrations (I), a series of
lines with slopes of Km/(Vmax ? Ki ? C) will be obtained. A
further plot of the slopes of the Dixon plot vs. reciprocal
substrate concentrations (1/C) will result in a line that passes
through the origin. From the slope of this line (and knowing
the Vmax and Km values), Ki can be estimated.
For kinetic studies of carnosine, the concentration-




Km + C + Kd ? C (5)
where Vmax is the maximal rate of carnosine uptake, Km is
the Michaelis constant, Kd is the rate constant for nonsatu-
rable transport, and C is the substrate (carnosine) concentra-
tion. To evaluate if more than one class of transporters was
operational for carnosine, a Woolf-Augustinsson-Hofstee
transformation of the saturable portion of carnosine uptake
was performed




Statistical comparisons were performed using analysis of
variance (ANOVA; SYSTAT v8.0, SPSS Inc., Chicago, IL),
and pairwise comparisons were made using Tukey’s test. A
probability of P # 0.05 was considered statistically significant.
Linear and nonlinear regression analysis were performed us-
ing SCIENTIST (v2.01, MicroMath Scientific Software, Salt
Lake City, UT) and a weighting factor of unity. The quality of
fit was determined by evaluating the coefficient of determi-
nation (r2), the standard error of parameter estimates and by
visual inspection of the residuals. Data are reported as mean
± SE, unless otherwise indicated.
RESULTS
Inhibition of GlySar Uptake
Previous work in our laboratory demonstrated that di-
peptide/mimetic uptake in the choroid plexus is mediated by
two transport systems (5,7). PEPT2-mediated uptake repre-
sents the Na+-independent portion of transport, which can be
isolated and optimized in the choroid plexus by buffer ma-
nipulations (i.e., using low-sodium Tris-MES buffer at pH
6.5). Still, under more physiologic conditions using a bicar-
bonate-based CSF buffer, pH 7.3 (5,7), PEPT2-mediated
transport represents a significant portion of the total uptake
of GlySar ($30%) and 5-aminolevulinic acid ($50%). There-
fore, to evaluate specific interactions between PEPT2 and
selected neuropeptides (Fig. 1), a low-sodium Tris-MES, pH
6.5 buffer was used for the inhibition studies. NAAG, CysGly,
GlyGln, KTP, and carnosine at 1.0 mM concentration all in-
hibit GlySar uptake (Fig. 2). Yet TRH, DKTP, GSH, and
homocarnosine do not inhibit GlySar uptake. The dipeptides
CysGly, GlyGln, KTP, and carnosine all inhibit 85–90% of
GlySar uptake while NAAG, a modified dipeptide, only in-
hibits 50% of GlySar uptake. Based on these results, dose-
response analyses were performed for NAAG, CysGly,
GlyGln, KTP, and carnosine. Table I shows the IC50 values
for each compound. NAAG has the highest IC50 value, about
0.6 mM, which compares well with only 50% inhibition at 1
mM concentration. The four remaining dipeptides have IC50
values ranging from 0.4 mM for carnosine to 5 mM for KTP.
The mechanism of inhibition for KTP was further exam-
ined because it had the lowest IC50 value, indicating that KTP
is the most potent inhibitor in our group of neuropeptides.
Figure 3 shows the Dixon plot of inhibition of GlySar uptake
by KTP. Three lines are generated corresponding to three
different concentrations of GlySar. These lines intersect
above the x-axis, indicating a Ki of 7.1 mM (represents the
median value). Replotting the slopes of the Dixon plot
against the inverse GlySar substrate concentrations is shown
Fig. 2. Effect of selected neuropeptides on the uptake rate of [14C]-
GlySar (0.94 mM GlySar in external media). Inhibitor concentrations
are 1.0 mM. Studies were performed using low-sodium Tris-MES
CSF buffer, pH 6.5. Data are expressed as mean ± SE (n 4 8 for
control; n 4 4 for inhibitors). ** p <0.01, *** p <0.001, as compared
to control.
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in the insert of Fig. 3, in which a line fit to the data points runs
through the origin. This replot indicates that KTP is a com-
petitive inhibitor of GlySar. From the slope of the line, and
given the Km and Vmax of GlySar, the Ki is estimated by this
method as 11.9 mM. The Ki may also be estimated by the
method of Cheng and Prusoff (11) in which Ki is equivalent to
IC50/(1 + C/Km) for a competitive inhibitor. The Ki is thus
estimated to be 5.1 mM. From these three determinations, the
Ki of KTP can be best estimated as 8.0 mM.
Carnosine Uptake
Because two transporters are known to transport dipep-
tides/mimetics in choroid plexus (5,7), we initially examined
the uptake of carnosine (0.022 mM [3H]carnosine in external
media) in both aCSF and low-sodium aCSF buffers. Carno-
sine uptake in the more physiologic aCSF buffer (represent-
ing both Na+-independent and Na+-dependent mechanisms)
was 0.0186 pmol/mg/min. In contrast, carnosine uptake in
low-sodium aCSF (representing the Na+-independent, PEPT2
mechanism) was 0.0112 pmol/mg/min. Thus, PEPT2-
mediated transport of carnosine represents 60% of the total
uptake. This, however, might be a minimal estimate of the
contribution of PEPT2 because the low-sodium aCSF buffer
can affect the Na+/H+ exchanger (8,9) which, in turn, can
affect PEPT2 activity by reducing the electrochemical proton
gradient. Regardless, a significant portion of carnosine trans-
port is mediated by PEPT2 under physiologic conditions in
choroid plexus.
To further evaluate the specific interaction between car-
nosine and PEPT2, studies with [3H]carnosine were subse-
quently performed in low-sodium Tris-MES buffer at pH 6.5.
Figure 4 shows the time-dependent uptake of [3H]carnosine
in rat choroid plexus. Uptake is linear for the first 2 min, thus
we chose 1 min for the uptake time in our subsequent experi-
ments. To verify that transport was specific for the PEPT2
transporter, we inhibited [3H]carnosine uptake with 1 mM
concentration of carnosine, GlySar, homocarnosine, L-
histidine, and b-alanine (Fig. 5). Only carnosine and GlySar
inhibited [3H]carnosine uptake. We also evaluated the con-
centration-dependent uptake of [3H]carnosine in choroid
plexus tissue in which the data were fitted to a model con-
taining one saturable component and one nonsaturable com-
ponent (Fig. 6). Based on that model (Eq. 5), we determined
the Km as 39.3 ± 14.0 mM, the Vmax as 73.9 ± 10.3 pmol/mg/
min, and the nonsaturable component Kd as 0.044 ± 0.008
ml/mg/min. Because PEPT1 is not present in choroid plexus
and the absence of sodium inactivates organic anion transport
(5,7), the nonsaturable component seems to be either diffu-
sion or an impurity in the radiolabel. The insert in Fig. 6
represents a Woolf-Augustinson-Hofstee transformation,
which is linear (r24 0.893), indicating a single class of trans-
porters. Thus, carnosine is transported by a high-affinity, low-
capacity transporter, which has the characteristics of PEPT2.
DISCUSSION
A diverse group of 9 neuropeptides were tested as in-
hibitors against the PEPT2-mediated uptake of GlySar in
choroid plexus. Our results demonstrate that choroidal
PEPT2 has significant affinity for some of these neuropep-
tides, and GlySar is inhibited by the neuropeptide kyotorphin
Fig. 3. Dixon plot of inhibition of [14C]GlySar by KTP. Studies were
performed using low-sodium Tris-MES CSF buffer, pH 6.5. Data are
expressed as mean (n 4 4). Lines generated by least squares regres-
sion. Insert is a replot of Dixon plot slopes vs. the reciprocal of the
GlySar concentration. Regression is linear (r24 0.911) with y-
intercept not significantly different than zero (p 4 0.728), indicating
that KTP is a competitive inhibitor of GlySar.
Table I. Dose-Response Analysis of Neuropeptide Inhibitorsa
Neuropeptide IC50 (mM)b r2
NAAG 615 ± 218 0.966
Carnosine 423 ± 43 0.982
CysGly 139 ± 14 0.983
GlyGln 14.1 ± 2.1 0.998
KTP 5.2 ± 1.3 0.997
a Inhibition of [14C]GlySar (1.88 mM GlySar in external media) by the
neuropeptides was fit to the model described in Eq. 2 (see text).
IC50 is the concentration of inhibitor that causes a 50% reduction in
GlySar uptake, and r2 is the coefficient of determination for the
fitted model. Inhibitor concentrations ranged from 0–10 mM for
NAAG, 0–1.0 mM for carnosine, 0–1000 mM for CysGly, 0–500 mM
for GlyGln, and 0–500 mM for KTP. Studies were performed in
low-sodium Tris-MES buffer, pH 6.5.
b Results are expressed as mean ± SE (n 4 4).
Fig. 4. Uptake amount of [3H]carnosine as a function of time in rat
lateral ventricle choroid plexus (0.022 mM carnosine in external me-
dia). Uptake is linear through 2 min, with y-intercept not significantly
different that zero (P 4 0.189). Studies were performed in low-
sodium Tris-MES CSF buffer, pH 6.5. Data are expressed as mean ±
SE (n 4 4).
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in a competitive manner. We also demonstrate that carnosine
uptake is mediated in part by choroid plexus PEPT2. Taken
as a whole, these results suggest that PEPT2 plays an impor-
tant role in neuropeptide homeostasis at the choroid plexus.
Only 5 of the 9 neuropeptides inhibited GlySar uptake,
namely NAAG, CysGly, GlyGln, KTP, and carnosine. In con-
trast, TRH, homocarnosine, GSH, and DKTP did not inhibit
GlySar uptake. TRH does not contain a free amino group
because of the cyclization of glutamine to pyroglutamine. Ex-
periments in sheep choroid plexus showed no TRH transport
(12) and Fujita et al. (13) showed no interaction between
TRH and PEPT2 in synaptosomes. Homocarnosine is similar
to carnosine except it has an additional methyl group between
the free amine and the carboxylic acid. According to Daniel et
al. (14), a prescribed backbone length between two ionized
groups (i.e., amino and carboxyl group) is important for sub-
strate recognition and transport by the intestinal peptide
transporter. Thus, it seems that similar structural features are
necessary for TRH or homocarnosine to interact with the
renal peptide transporter PEPT2. GSH contains a highly re-
active sulfhydryl group that is easily oxidized to the GSH-
GSH dimer under physiological conditions. Although dimer-
ization can be minimized under conditions of high acidity and
low temperature, we were unable to pursue this option be-
cause of tissue viability. Thus, GSH may not show an effect in
our system because it dimerizes to a hexapeptide that would
not be transported. Further studies in a system that permits
control of the dimerization process would help clarify if GSH
is indeed a substrate of PEPT2.
DKTP is particularly interesting because it is a structural
analog of KTP (D-arginine replaces L-arginine at the carboxy
terminus). PEPT2 prefers L-amino acids (2), which could ex-
plain the difference in affinity for DKTP and KTP. DKTP has
6 times the analgesic effect of KTP (15), which can be attrib-
uted to reduced metabolism or clearance. If PEPT2 serves a
clearance function in the CSF, then KTP would be cleared
much faster that DKTP, thus allowing DKTP to accumulate
and have greater pharmacological activity in the brain. Al-
though this scenario is speculative, the relationship between
transport properties and pharmacological effect in the central
nervous system has already been shown in synaptic transmis-
sion of catecholamines (i.e., norepinephrine) (16).
The IC50 values for the 5 compounds that inhibit GlySar
uptake vary from 5 to 615 mM. The weakest inhibitor,
NAAG, is the most modified dipeptide with an extra acetyl
group on the free amine, resulting in a secondary rather than
primary amine. The next weakest inhibitor is carnosine, which
contains a non-standard b-alanyl residue. The remaining
three inhibitors (CysGly, GlyGln, and KTP) are all L-
dipeptides with no modifications. All 3 dipeptides had IC50
values at or below the Km (129 mM) of GlySar, a modified
dipeptide. Although all dipeptides are transported by PEPT2,
their affinities for PEPT2 are quite different. A thorough
examination of the effect of amino acid composition on di-
peptide affinity for PEPT2 would be needed to draw further
conclusions about the differences in IC50 values.
KTP was determined to be a competitive inhibitor of the
PEPT2-mediated uptake of GlySar. The Ki of KTP in whole
tissue choroid plexus was approximately 8.0 mM. This sug-
gests that PEPT2 has high affinity for KTP, and that KTP is
most likely transported by PEPT2. Human CSF levels of KTP
are in the nM range (1.2 nM for healthy subjects, 0.24 nM for
persistent pain subjects) (17,18). Thus, PEPT2 function could
be involved in pain tolerance through regulation of KTP lev-
els in the CSF. As alluded to above, DKTP may provide
increased analgesia because of its reduced CSF clearance me-
diated by PEPT2. In situ analyses of KTP and DKTP trans-
port and metabolism at the choroid plexus would be useful to
further evaluate this premise. Finally, Fujita et al. (13) also
demonstrated that KTP was a competitive inhibitor (Ki 4 30
mM) of PEPT2-mediated GlySar uptake in synaptosomes pre-
pared from rat cerebellum.
Carnosine uptake in kidney brush-border membrane
vesicles has been demonstrated (19), however, the kinetic pa-
rameters of transport by PEPT2 have not been reported. In
this study, we have shown that PEPT2 mediates carnosine
uptake is isolated choroid plexus. We also demonstrated that
Fig. 6. Concentration-dependent uptake rate of [3H]carnosine (10-
1500 mM total carnosine in external media). Predicted curves are
generated using Vmax, Km and Kd values reported in text (r2$
0.987). Insert is Woolf-Augustinsson-Hofstee plot, which is linear
(r24 0.893). Studies were performed using low-sodium Tris-MES
CSF buffer, pH 6.5. Data are expressed as mean ± SE (n 4 4). Error
bars were omitted for clarity.
Fig. 5. Effect of selected inhibitors on the uptake rate of [3H]carno-
sine (0.022 mM carnosine in external media). Inhibitor concentrations
are 1.0 mM. Studies were performed using low-sodium Tris-MES
CSF buffer, pH 6.5. Data are expressed as mean ± SE (n 4 8 for
control; n 4 4 for inhibitors). *** P < 0.001, as compared to control.
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PEPT2-mediated carnosine uptake represents at least 60% of
total uptake under physiologic conditions, and carnosine up-
take is concentration-dependent. The Km is about 40 mM
suggesting a high affinity transporter, and the Vmax is about
75 pmol/mg/min suggesting a low capacity transporter. Under
linear conditions, about 98% of carnosine is transported by
the saturable component. Carnosine uptake reached a pla-
teau concentration by 4 min with a value of 0.055 pmol/mg.
This corresponds to a tissue to media ratio of 2.5:1, suggesting
that carnosine is actively accumulated in choroid plexus. Al-
though carnosine has a relatively high IC50 value against Gly-
Sar, it has a faster initial uptake rate than GlySar (7).
To ensure that we were measuring carnosine uptake by
PEPT2, we evaluated 5 potential inhibitors. Both carnosine
and GlySar inhibited [3H]carnosine uptake. In contrast, ho-
mocarnosine and the amino acid constituents of carnosine,
L-histidine and b-alanine, did not inhibit [3H]carnosine up-
take. These results indicate that carnosine metabolism is not
a confounding factor in the interpretation of our data. In
addition, PHT1 does not appear to mediate carnosine uptake
because of the lack of inhibition by L-histidine at concentra-
tions 50 times the Km for L-histidine (6). These findings dem-
onstrate that carnosine is being transported by PEPT2, and
the process is specific.
In the kidney, PEPT2 works in concert with many pep-
tidases that degrade large proteins into small di- and tripep-
tide fragments for reabsorption from the kidney lumen (3,20).
It has been shown that many of the same peptidases present
in kidney microvilli are present in choroid plexus brush bor-
der membranes (21). The presence of peptidases in the cho-
roid plexus suggests that larger peptides are broken down in
this tissue before being transported by PEPT2. Although the
present study focused specifically on two- and three-amino-
acid neuropeptides, larger neuropeptides may be digested by
peptidases and then transported by PEPT2.
The regulation of choroid plexus and CSF pH is of par-
ticular interest because PEPT2-mediated peptide uptake is
pH dependent in this tissue (7). Choroid plexus cell pH is
affected by various factors including external pH, sodium, and
bicarbonate concentrations (22,23). Additionally, pH regula-
tion is compromised in vitro (22). Normally, bulk CSF pH is
similar to that in plasma but choroid plexus epithelial cell pH
is about 0.3 units less than bulk CSF (22). However, whether
there are local pH gradients, for example at the choroidal
apical membrane, is unknown (24). pH gradients do exist in
the kidney and intestine, both of which exhibit proton-
dependent peptide transport. In this regard, studies in intes-
tinal and renal brush border membrane vesicles indicate that
PEPT2-mediated transport is modulated by extracellular pH
(19,25). Further, Wang et al. (24) demonstrated that external
proton concentrations markedly affect brain-derived PEPT2
when expressed in Xenopus laevis oocytes.
Based on our findings, PEPT2 mediates a portion of neu-
ropeptide transport in choroid plexus, suggesting that it might
be involved in the biodistribution of peptidomimetics in the
CSF and blood. According to Huang (26) in which dipeptide
accumulation occurred on the apical side of the choroid
plexus, we speculate that PEPT2 could be located on the
CSF-facing membrane. Positioned there, PEPT2 could regu-
late the clearance of neuropeptides, unneeded peptide frag-
ments, and peptidomimetics from the brain. Our data indicate
that the PEPT2-mediated clearance of carnosine is 2 ml/min at
physiologic pH, a value similar to CSF bulk flow in adult rats.
However, this is only a rough estimate since we are comparing
in vitro choroidal uptake versus in vivo CSF flow. Also, if the
apical microenvironment pH, as observed in the small intes-
tine (27) and presumably kidney, is more acidic then carno-
sine clearance would increase 3–5-fold. Understanding how
PEPT2 affects the distribution of compounds across the cho-
roid plexus barrier will help in future drug design and the
more effective treatment of CNS disorders. For example, just
as known P-glycoprotein inhibitors are given orally to pro-
mote P-glycoprotein substrate uptake in the intestine (28), so
too could PEPT2 inhibitors be used to limit CSF clearance of
desirable PEPT2 substrates.
In summary, our studies are unique in describing the
interaction of a diverse group of neuropeptides with the pro-
ton/oligopeptide symporter, PEPT2, in isolated choroid
plexus. We demonstrate, for the first time, the competitive
inhibition of GlySar uptake by KTP as well as the direct
transport of carnosine in this tissue. These findings suggest
that choroidal PEPT2 plays a role in neuropeptide homeo-
stasis of cerebrospinal fluid. Our laboratory is in the process
of collecting immunocytochemical data regarding the precise
cellular location of PEPT2 and developing choroid plexus
epithelial cells in primary culture with the aim of studying the
directionality of peptide/mimetic transport by PEPT2 (29).
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